About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Los Angeles | 16,901 Studies Near You | Clareo Health

Clinical Trials LocationsLos Angeles

Clinical Trials in Los Angeles

Discover 16,901 clinical trials near Los Angeles, California. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 6241-6260 of 16,901 trials

COMPLETEDNA< 1 mile

Treatment of Peripheral Arterial Hemorrhage With Lava LES (The LAVA Study)

NCT04649255

To evaluate the safety and effectiveness of the Lava LES for the embolic treatment of arterial hemorrhage in the peripheral vasculature.

Peripheral Arterial Hemorrhage

BlackSwan Vascular, Inc.113 participantsStarted Apr 2021

Irvine, California, United States • Los Angeles, California, United States • Miami, Florida, United States +6 more locations

Active Not RecruitingNA< 1 mile

Safety and Effectiveness Study of the Zenflow Spring System

NCT04987138

Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.

BPH (Benign Prostatic Hyperplasia)Lower Urinary Tract Symptoms (LUTS)

Zenflow, Inc.279 participantsStarted Sep 2021

Los Angeles, California, United States • Glenview, Illinois, United States • Las Vegas, Nevada, United States +4 more locations

Find Trials by Condition in Los Angeles

Breast Cancerin Los Angeles Lung Cancerin Los Angeles Prostate Cancerin Los Angeles Colorectal Cancerin Los Angeles Melanomain Los Angeles Leukemiain Los Angeles Lymphomain Los Angeles Pancreatic Cancerin Los Angeles Ovarian Cancerin Los Angeles Brain Cancerin Los Angeles

Data from ClinicalTrials.govTerms

COMPLETEDPhase 1< 1 mile

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT04539470

This is a Phase Ib, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of Efmarodocokin Alfa and to make a preliminary assessment of activity of Efmarodocokin Alfa in combination with standard-of-care (SOC) in the prevention of acute graft-versus-host disease (aGVHD) in participants undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

Acute Graft-versus-host Disease

Genentech, Inc.18 participantsStarted Nov 2020

Duarte, California, United States • Los Angeles, California, United States • Miami, Florida, United States +5 more locations

RECRUITINGPhase 1/2< 1 mile

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

NCT05519293

This is a phase I/IIa, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of H002 when given orally in patients with active EGFR mutation locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will contain two parts: Part A is dose escalation phase (i.e., Phase I) and Part B is dose expansion phase (i.e., Phase IIa).

Non-small Cell Lung Cancer

RedCloud Bio76 participantsStarted Dec 2022

Los Angeles, California, United States • Boston, Massachusetts, United States • New York, New York, United States +1 more locations

TERMINATEDPhase 1/2< 1 mile

Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

NCT01458405

The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.

Myocardial Infarction

Capricor Inc.135 participantsStarted Nov 2012

Birmingham, Alabama, United States • Huntsville, Alabama, United States • La Jolla, California, United States +29 more locations

TERMINATEDPhase 26.3 miles

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

NCT03472560

This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum containing therapy, and in treatment naïve patients with advanced or metastatic urothelial cancer, who are ineligible for cisplatin containing chemotherapy for their advanced disease.

Non-Small Cell Lung CancerUrothelial Cancer

Pfizer61 participantsStarted May 2018

Glendale, Arizona, United States • Goodyear, Arizona, United States • Phoenix, Arizona, United States +36 more locations

COMPLETEDNA9.0 miles

Evaluation of the SHARE! Peer Toolkit Training

NCT05382416

SHARE! the Self-Help and Recovery Exchange will engage peer workers in their Peer Toolkit training, which is designed to improve the performance of peer workers in their provision of peer support. The Peer Toolkit training currently has a waitlist of peer workers interested in taking the course for professional development purposes. These peer workers and their supervisors will be invited to complete a web-based survey at baseline and 4-month follow-up. Peer workers will be randomly assigned to enroll in the Peer Toolkit training immediately or after the follow-up survey. Analyses will compare participants who had the opportunity to complete the training to those still waiting to start the training. This study will inform the use of the Peer Toolkit as a training mechanism to build the capacity of peer workers in the mental health workforce.

The University of Texas Health Science Center, Houston272 participantsStarted May 2022

Culver City, California, United States

COMPLETEDNA9.0 miles

Supporting the Mental Health Workforce

NCT03709537

Emotional Health Association will engage Los Angeles County Department of Mental Health providers that employ peer workers in a training and technical assistance intervention designed to support, increase, and retain an effective peer workforce. This intervention consists of a Co-Learning Collaborative, several training sessions, and the creation of Implementation Teams. Peer workers will also be encouraged to attend Recovery International, an established network of self-help support groups for mental health. Dr. Louis Brown will lead an evaluation of the efficacy of the intervention. This study will inform the use of peer workers as a component of the mental health workforce.

The University of Texas Health Science Center, Houston366 participantsStarted Oct 2018

Culver City, California, United States

RECRUITINGPhase 19.1 miles

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain

NCT06361485

This is a Pilot Study that is an open label, prospective, non-controlled study in which the safety and feasibility of Wharton's Jelly (WJ) allograft will be evaluated in 100 participants suffering with low back pain.

R3 Stem Cell100 participantsStarted Mar 2024

Scottsdale, Arizona, United States • Beverly Hills, California, United States • New York, New York, United States +1 more locations

TERMINATEDPhase 116 miles

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

NCT05061537

This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 \[PD-1\] antibody), in patients with selected locally advanced or metastatic solid tumors who have exhausted all available standard of care therapies available to them. The study consists of 2 parts: Part 1 dose escalation for PF-07263689 monotherapy (Part 1A) and in combination with sasanlimab (Part 1B), followed by Part 2 dose expansion for the combination therapy.

Renal Cell CancerMelanomaNon-Small-Cell Lung Cancer+7 more

Pfizer13 participantsStarted Oct 2021

Duarte, California, United States • New York, New York, United States • New York, New York, United States

COMPLETEDNA16 miles

Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer

NCT02054741

This cluster randomized clinical trial compares a geriatric assessment intervention with usual care for reducing cancer treatment toxicity in older patients with cancer that has spread to other places in the body. A geriatric assessment may identify risk factors for cancer treatment toxicity and may improve outcomes for older patients with advanced cancer.

Adult Solid NeoplasmToxicityLymphoma

Supriya Mohile733 participantsStarted Jul 2014

Duarte, California, United States • Newark, Delaware, United States • Honolulu, Hawaii, United States +20 more locations

UNKNOWNPhase 216 miles

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

NCT02232516

The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymphoma (PTCL) who have not been previously treated for this cancer. Currently, there is no standard treatment for patients with PTCL; the most common treatment used is a combination of drugs called CHOP, but this can be a difficult treatment to tolerate because of side effects, and is not particularly effective for most patients with PTCL. Romidepsin (Istodax®) is a type of drug called an HDAC inhibitor. It interacts with DNA (genetic material in cells) in ways that can stop tumors from growing. It is given as an infusion through the veins. Lenalidomide (Revlimid®) is a type of drug known as an immunomodulatory drug, or IMID for short. This drug affects how tumor cells grow and survive, including affecting blood vessel growth in tumors. It is given as an oral tablet (by mouth).

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+14 more

Northwestern University30 participantsStarted Jun 2015

Duarte, California, United States • New Haven, Connecticut, United States • Chicago, Illinois, United States +2 more locations

TERMINATEDPhase 216 miles

A Study of Olaparib and Durvalumab in Prostate Cancer

NCT03810105

The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.

Prostate Cancer

Memorial Sloan Kettering Cancer Center5 participantsStarted Mar 2019

Duarte, California, United States • Chicago, Illinois, United States • Detroit, Michigan, United States +5 more locations

COMPLETEDPhase 120 miles

A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

NCT03815695

FT-4202 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias. This initial study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of FT-4202 in the context of Phase 1 studies in healthy volunteers and sickle cell disease patients. The effects of food on the absorption of FT-4202 will also be evaluated in healthy volunteers.

Healthy VolunteersSickle Cell Disease

Forma Therapeutics, Inc.130 participantsStarted Dec 2018

Little Rock, Arkansas, United States • Long Beach, California, United States • Oakland, California, United States +15 more locations

COMPLETEDPhase 120 miles

A Phase 1 Study of ONO-2020 in Healthy Participants

NCT05507515

The purpose of this FIH study is to evaluate the safety, tolerability and pharmacokinetics of ONO-2020 in healthy adult participants. This FIH study consists of five parts (Parts A-E) to study single or multiple doses of ONO-2020 in healthy participants, including elderly and Japanese participants, as well as the food effect on the PK of ONO-2020. These data will support the clinical development program and help inform dose selection in future studies.

Healthy Volunteers

Ono Pharmaceutical Co. Ltd132 participantsStarted Jul 2022

Cypress, California, United States

COMPLETEDPhase 346 miles

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

NCT04917874

This is a 112-week (approximately two-year) open-label extension study of Beremagene Geperpavec (B-VEC), for participants aged 2 months and older, who have been diagnosed with Dystrophic Epidermolysis Bullosa (DEB). Participants will be dosed weekly with the topical B-VEC therapy. The primary endpoint will be to assess long term safety and tolerability of the topical gene therapy. The study is for those who participated in Phase 3 study, as well as, new participants who were unable to participate in the Phase 3 study, who meet all enrollment criteria.

Dystrophic Epidermolysis BullosaDEB - Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa+1 more

Krystal Biotech, Inc.47 participantsStarted May 2021

Rancho Santa Margarita, California, United States • Redwood City, California, United States • Coral Gables, Florida, United States +3 more locations

COMPLETED87 miles

Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy

NCT03761615

The overall goal of this study is to enroll pregnant women with type 1 diabetes and follow their glycemic outcomes prospectively throughout pregnancy and into the post-partum period. The investigators anticipate that when compared to subjects using an Artificial pancreas system (AP) as part of a future protocol, this comparator group of subjects undergoing usual care will exhibit less time in target continuous glucose monitoring (CGM) glucose range defined as 63-140 mg/dL and an increased duration of hypoglycemia with CGM glucose \<63 mg/dL.

Type 1 Diabetes MellitusPregnancy in Diabetics

Sansum Diabetes Research Institute25 participantsStarted Nov 2018

Santa Barbara, California, United States • Rochester, Minnesota, United States • New York, New York, United States

COMPLETEDPhase 3100 miles

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

NCT04279314

To investigate the safety and tolerability of long-term treatment with oral trofinetide in girls and women with Rett syndrome

ACADIA Pharmaceuticals Inc.154 participantsStarted Jan 2020

Birmingham, Alabama, United States • Phoenix, Arizona, United States • La Jolla, California, United States +18 more locations

COMPLETEDNA111 miles

Evaluation of Product Performance of a New Silicone Hydrogel Multifocal Contact Lens

NCT05660577

The objective of this study is to evaluate the product performance of a new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens, when worn by current soft contact lens wearers on a daily disposable wear basis

Myopia and Hyperopia and Presbyopia

Bausch & Lomb Incorporated301 participantsStarted Nov 2022

San Diego, California, United States • San Francisco, California, United States • Denver, Colorado, United States +17 more locations

No Longer Available336 miles

Expanded Access Program of Surufatinib

NCT04814732

This treatment protocol is intended to provide early access of surufatinib to patients with locally advanced or metastatic NETs for whom, in the opinion of their treating physician, other treatment options or surufatinib clinical trials in this indication are unsuitable. This EAP is currently available in the US only.

Neuroendocrine Tumors

Denver, Colorado, United States • Baltimore, Maryland, United States • Detroit, Michigan, United States +8 more locations

PreviousPage 313 of 846Next

Diabetes

in Los Angeles

Heart Diseasein Los Angeles